Q-omics provides the consensus-scored ITIH4 profile across patient tissues and cancer cell-line models. ITIH4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ITIH4 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, ITIH4 protein abundance shows 22,738 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where ITIH4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ITIH4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ITIH4 survival associations across molecular data types. ITIH4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ITIH4 RNA expression–survival associations across cancer types. High ITIH4 expression shows unfavorable associations in KIRC, ACC, CHOL and STAD, but favorable associations in BLCA and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ITIH4 RNA expression.
This table summarizes ITIH4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ITIH4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ITIH4 shows lower tumor expression in BRCA, KICH, THCA, LUSC and CHOL and higher tumor expression in KIRC. The KIRC box plot shows higher ITIH4 RNA expression in tumor versus normal tissue (log2 FC = +0.264, t-test p < 0.001).
This table shows molecular features associated with ITIH4 in patient tissues and cancer cell lines. In patient samples, ITIH4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ITIH4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
